CALR and myeloproliferative neoplasm: The idea of a vaccination therapy and strong immune response against mutant CALR is supported by recent findings about the potency of secreted mutant CALR acting as a cytokine to interact and bind to the thrombopoietin receptor on neighboring MPN-cells.